Live feed17:30:00·395dPRReleasevia QuantisnowMerus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCCByQuantisnow·Wall Street's wire, on your screen.MRUS· Merus N.V.Health Care
